Durable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and Daratumumab

Key Clinical Message CNS myelomatous involvement is a rare complication of multiple myeloma with dismal outcome. This disease's optimal treatment is unclear. Combined approach of systemic therapy, radiotherapy, and intrathecal injections chemotherapy should be considered and autologous stem cel...

Full description

Saved in:
Bibliographic Details
Published inClinical case reports Vol. 6; no. 4; pp. 723 - 728
Main Authors Elhassadi, Ezzat, Murphy, Maurice, Hacking, Dayle, Farrell, Michael
Format Journal Article
LanguageEnglish
Published England John Wiley & Sons, Inc 01.04.2018
John Wiley and Sons Inc
Subjects
Case Report
Case Reports
CNS plasmacytoma
Daratumumab
extramedullary myeloma
Immunotherapy
intrathecal chemotherapy
Monoclonal antibodies
radiotherapy
Targeted cancer therapy
radiotherapy
intrathecal chemotherapy
extramedullary myeloma
Daratumumab
CNS plasmacytoma
Online AccessGet full text

Cover

More Information
Summary:Key Clinical Message CNS myelomatous involvement is a rare complication of multiple myeloma with dismal outcome. This disease's optimal treatment is unclear. Combined approach of systemic therapy, radiotherapy, and intrathecal injections chemotherapy should be considered and autologous stem cell transplant consolidation is offered to eligible patients. The role of Daratumumab in this disease deserves further evaluation. CNS myelomatous involvement is a rare complication of multiple myeloma with dismal outcome. This disease's optimal treatment is unclear. Combined approach of systemic therapy, radiotherapy, and intrathecal injections chemotherapy should be considered and autologous stem cell transplant consolidation is offered to eligible patients. The role of daratumumab in this disease deserves further evaluation.
ISSN:2050-0904
2050-0904
DOI:10.1002/ccr3.1451